The company develops products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients, with lead candidates including PL-14 (nasal allergies blocker), PL-15 (COVID-19), and PL-16 (influenza blockers). Recent pre-clinical research released in January 2026 demonstrated PL-14's significant allergen-blocking performance compared to standard comparators.
Cyborg Score Rationale
Polyrizon demonstrates promising pre-clinical technology and positive allergen-blocking data, but remains a pre-clinical stage company with no approved products and recent regulatory challenges. The company faced delisting concerns in May 2025 due to shareholder dilution from a March 2025 securities offering, though it regained Nasdaq compliance in August 2025. Execution risk remains high.
Top Insights
PL-14 demonstrated significantly reduced allergen transfer compared to hydroxypropyl methylcellulose (HPMC) at all tested time points, with statistically significant p-values ≤ 0.0042 (January 2026).
Company regained full Nasdaq compliance in August 2025 after addressing minimum bid price requirements and conditions from the Nasdaq Hearings Panel.
Company is developing enhanced aspects of its C&C hydrogel technology including bioadhesion and prolonged retention at the nasal deposition site for intranasal drug delivery.
Development stage company with pipeline of three named product candidates targeting allergies, COVID-19, and influenza indications via intranasal delivery.